Table 2.
Association of biomarkers with left ventricular ejection fraction after correction for age, renal function, body mass index, history of or current cardiovascular disease, treatment with anti‐hormonal therapy and treatment with radiotherapy in survivors treated with chemotherapy and/or radiotherapy
| Biomarker | Standardized beta | P‐value |
|---|---|---|
| TNFSF13B | −0.18 | 0.02 |
| Gal4 | −0.11 | 0.184 |
| MCP1 | −0.21 | 0.011 |
| KLK6 | 0.01 | 0.864 |
| FABP4 | −0.2 | 0.033 |
| GDF15 | −0.26 | 0.002 |
| SCGB3A2 | 0.03 | 0.739 |
| RARRES2 | −0.2 | 0.017 |
| CXCL16 | −0.19 | 0.019 |
| PI3 | −0.17 | 0.041 |
| IGFBP7 | −0.18 | 0.026 |
| CNTN1 | −0.15 | 0.06 |
| TIMP4 | −0.08 | 0.294 |
| OPN | −0.16 | 0.04 |
| PCSK9 | −0.16 | 0.041 |
| PLC | −0.21 | 0.011 |
| CTSZ | −0.11 | 0.16 |
| Gal3 | −0.14 | 0.079 |
| TFPI | −0.15 | 0.05 |
CNTN1, contactin‐1; CTSZ, cathepsin Z; CXCL16, Chemokine (C‐X‐C motif) ligand 16; FABP4, fatty acid binding protein 4; Gal3, galectin‐3; Gal4, galectin‐4; GDF15, growth differentiation factor 15; KLK, kallikrein‐6; IGFBP7, insulin‐like growth factor‐binding protein 7; MCP1, monocyte chemoattractant protein 1; OPN, osteopontin; PCSK9, proprotein convertase subtilisin/kexin type 9; PI3, peptidase inhibitor 3; PLC, perlecan; RARRES2, retinoic acid receptor responder protein 2; SCGB3A2, secretoglobin family 3A member 2; TFPI, tissue factor pathway inhibitor; TIMP4, tissue inhibitor of metalloproteinase 4; TNFSF13B, tumour necrosis factor super family member 13b.